Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement

Rhea-AI Summary

Pluri (Nasdaq, TASE: PLUR) announced a private placement on March 26, 2026 in which an entity beneficially owned by Chairman Alejandro Weinstein will invest an additional $2.5 million at a 30% premium to the March 24, 2026 market price.

The offering consists of 625,000 common shares and warrants to purchase up to 625,000 common shares at a combined purchase price of $4.00 per share/warrant; warrants are exercisable immediately at $4.25 and expire 18 months after closing. Proceeds are for general working capital and corporate purposes.

Positive

• Chairman investment at a 30% premium to market
• $2.5M gross proceeds from the private placement
• Issuance includes 625,000 immediately exercisable warrants

Negative

• Potential dilution from 625,000 shares plus 625,000 warrants
• Warrants expire in 18 months, creating near-term overhang risk

Key Figures

New investment amount: $2.5 million Shares issued: 625,000 common shares Warrants issued: 625,000 warrants +5 more

8 metrics

New investment amount $2.5 million Additional private placement by Chairman’s entity at 30% premium

Shares issued 625,000 common shares Offered in March 2026 private placement unit

Warrants issued 625,000 warrants Companion warrants in private placement unit

Unit purchase price $4.00 per share+warrant Combined price in March 2026 private placement

Revenue $514,000 Six months ended Dec 31, 2025 (vs. $511,000 prior year)

Net loss $13.0 million Six months ended Dec 31, 2025 (vs. $9.1M prior year)

Cash and equivalents $13.6 million Balance as of Dec 31, 2025

EIB loan principal $23.5 million Loan due June 1, 2026, excluding $4.3M accrued interest

Market Reality Check

Price: $3.33 Vol: Volume 1,166 is well belo...

low vol

$3.33 Last Close

Volume Volume 1,166 is well below the 20-day average of 6,163 (about 0.19x typical activity), suggesting a modest pre-news liquidity backdrop. low

Technical Shares at $3.33 are trading below the 200-day MA of $4.10, despite the positive insider investment at a premium.

Peers on Argus

Biotech peers show mixed performance, with several names in the group down (e.g....

3 Up

Biotech peers show mixed performance, with several names in the group down (e.g., LVTX -3.87%, IPSC -9.21%, LTRN -0.89%) and others up (PEPG +2.31%). This contrasts with PLUR’s +9.18% move and points to a stock-specific reaction to the insider private placement.

Historical Context

5 past events · Latest: Feb 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 18	China patent grant	Positive	-1.1%	China patent for 3D immune cell expansion extending global IP family.
Jan 22	CDMO program milestone	Positive	+9.3%	Completion of first Resbiomed phase for placenta-derived biomaterials.
Dec 22	CDMO collaboration expansion	Positive	-2.9%	Expanded Remedy Cell collaboration with clinical-grade manufacturing runs.
Dec 09	Chairman appointment & raise	Positive	+9.9%	Alejandro Weinstein named Chairman with concurrent $2.5M private placement.
Nov 13	Industry awards	Positive	-6.1%	Multiple industry honors and expectation of a 40,000 NIS government grant.

Pattern Detected

Recent history shows mostly positive operational or strategic news, but price reactions have been mixed, with three negative and two positive moves following upbeat announcements.

Recent Company History

Over the last several months, Pluri has reported IP expansion, CDMO progress, and strategic leadership changes. A China patent grant for its 3D immune cell expansion platform on Feb 18, 2026 saw a modest decline, while completion of the first Resbiomed program phase on Jan 22, 2026 coincided with a +9.3% move. The December 2025 chairman appointment and related $2.5M private placement produced a +9.9% reaction. Awards and collaborations occasionally met with selling, underscoring inconsistent follow-through despite generally constructive news.

Regulatory & Risk Context

Active S-3 Shelf · $724,686

Shelf Active

Active S-3 Shelf Registration 2025-09-17

$724,686 registered capacity

An effective S-3 shelf has been filed covering resale of 3,425,488 common shares by selling shareholders. Pluri would not receive proceeds from those resales but could receive approximately $724,686 if certain outstanding warrants and pre-funded warrants are exercised for cash at stated exercise prices. The prospectus highlights the speculative nature of the investment and details additional option, warrant and RSU overhang.

Market Pulse Summary

This announcement highlights another $2.5 million insider-led private placement at a 30% premium, ec...

Analysis

This announcement highlights another $2.5 million insider-led private placement at a 30% premium, echoing a similar December 2025 transaction. The deal adds 625,000 shares and 625,000 warrants at a $4.00 unit price, providing working capital for a company that reported a $13.0M net loss and only $13.6M in cash over six months. Investors may track how this capital raise interacts with the $23.5M EIB loan due June 2026 and whether ongoing strategic initiatives translate into revenue growth and improved liquidity.

Key Terms

securities purchase agreement, private placement, warrants, exercise price, +2 more

6 terms

securities purchase agreement financial

"has entered into a Securities Purchase Agreement with Pluri for an additional"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

private placement financial

"The Securities Purchase Agreement relates to a private placement offering consisting"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

warrants financial

"and warrants to purchase up to 625,000 common shares of the Company"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

exercise price financial

"The warrants are exercisable immediately upon closing of the transaction at an exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

regulation d regulatory

"in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act ... and/or Regulation D promulgated thereunder"

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

section 4(a)(2) regulatory

"in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act"

Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

AI-generated analysis. Not financial advice.

HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by Alejandro Weinstein, Chairman of the Board and one of the Company’s largest shareholders, has entered into a Securities Purchase Agreement with Pluri for an additional $2.5 million investment in the Company at a 30% premium to the market price on March 24, 2026.

This additional investment follows Mr. Weinstein’s prior $2.5 million investment announced in connection with his appointment as Chairman of the Board, and further underscores his continued support in Pluri’s strategy, underlying asset base, and long-term value creation opportunity.

"Making an additional investment in Pluri reflects my view that the Company holds a unique combination of highly valuable assets, technology, and capabilities," said Alejandro Weinstein, Chairman of the Board of Pluri. "My goal is to help the Company unlock that value through focused execution, strategic prioritization, and the advancement of the current and future opportunities that can further strengthen Pluri’s momentum."

Yaky Yanay, Chief Executive Officer and President of Pluri, commented: "I believe Alejandro’s investment is a strong vote of confidence in the value of Pluri’s assets, platform, and future opportunities. We share the goal of unlocking this value through focused execution, strategic prioritization, and advancement of the initiatives we believe can create meaningful shareholder value."

The Securities Purchase Agreement relates to a private placement offering consisting of: 625,000 common shares, par value $0.00001 per share of the Company, and warrants to purchase up to 625,000 common shares of the Company The combined purchase price for each common share and common warrant is $4.00. The warrants are exercisable immediately upon closing of the transaction at an exercise price of $4.25 per share and will be exercisable until the expiration of the eighteen-month anniversary of the closing of the transaction. The gross proceeds to the Company from this transaction are expected to be approximately $2.5 million. Pluri intends to use the proceeds from the private placement for general working capital and general corporate purposes.

The offer and sale of the foregoing securities is being made in a private placement in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, or applicable state securities laws. Accordingly, the securities offered in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Mr. Alejandro Weinstein

Mr. Weinstein, a prominent investor, has built and scaled global companies across healthcare, biotechnology, and wellness, including transforming CFR Pharmaceuticals into a multinational group later acquired by Abbott for $2.9 billion, and founding leading investment platforms such as WM Partners, Olive Tree Ventures, and Vanterra Ventures, which is active in functional food and nutrition innovation. His proven ability to grow companies, execute strategic transactions, and lead value driven organizations makes him a strong candidate to serve as Chairman.

About Pluri Inc:

Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions.

The Company drives innovation in regenerative medicine, foodtech, agtech, and offers CDMO services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, the Company is using forward-looking statements when it discusses the belief that the Company holds a unique combination of highly valuable assets, technology, and capabilities, the belief that the investment is a strong vote of confidence in the value of Pluri’s assets, platform, and future opportunities , the potential of the Company’s ventures, the Company’s focus on sharpening execution, advancing commercialization and building long-term value for its shareholders, and the expected use of proceeds from the private placement and the timing and completion of the private placement. These forward-looking statements and their implications are based on the current expectations only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the ability to fulfill the closing conditions for the private placement, changes in consumer preferences or aesthetics industry trends; the Company or each of its subsidiaries may encounter delays or obstacles in the launch, development, manufacturing, or commercialization of its food/agtech products; regulatory hurdles in new markets; the efficacy or safety of cell-derived products may not meet expectations; shifts in strategic priorities by the Company or its partners/collaborators, including these global food and agtech companies; challenges in marketing or brand alignment; intellectual property risks; unforeseen scientific or operational difficulties; inability to attract or retain key personnel; and competitive pressures that could impact market adoption or pricing; the Company’s ability to satisfy closing conditions, consummate the private placement on the expected terms or timeline, or at all; and the Company’s ability to use the proceeds as anticipated. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission.

Contacts
Investors: investor.relations@pluri-biotech.com
U.S. Media: Berry Brady at berry@quantum-corp.com

FAQ

What exactly did Pluri (PLUR) announce on March 26, 2026 regarding financing?

Pluri announced a private placement raising approximately $2.5 million. According to the company, the offering is 625,000 common shares plus warrants to buy 625,000 shares at a combined price of $4.00 per share/warrant.

Who is investing in Pluri (PLUR) and why does it matter to shareholders?

An entity beneficially owned by Chairman Alejandro Weinstein is investing an additional $2.5 million. According to the company, this follows a prior $2.5 million commitment and signals continued insider support for Pluri's strategy.

What are the warrant terms in Pluri's (PLUR) private placement on March 26, 2026?

Warrants issued are exercisable immediately with an exercise price of $4.25. According to the company, the warrants can be exercised until the 18-month anniversary of the closing.

How many shares will Pluri (PLUR) issue in the private placement and what is the combined price?

The private placement consists of 625,000 common shares and matching warrants at a combined purchase price of $4.00 per share and warrant. According to the company, gross proceeds are approximately $2.5 million.

What will Pluri (PLUR) use the $2.5 million proceeds for and does it change guidance?

Pluri intends to use proceeds for general working capital and general corporate purposes. According to the company, no specific guidance change or dedicated program funding was disclosed in the announcement.